Back to top

Tandem Diabetes (TNDM) Outpaces Stock Market Gains: What You Should Know

Read MoreHide Full Article

In the latest trading session, Tandem Diabetes (TNDM - Free Report) closed at $62.37, marking a +0.68% move from the previous day. This move outpaced the S&P 500's daily gain of 0.21%. Elsewhere, the Dow gained 0.64%, while the tech-heavy Nasdaq lost 0.05%.

Heading into today, shares of the insulin pump maker had lost 2.26% over the past month, lagging the Medical sector's loss of 0.07% and the S&P 500's gain of 2.57% in that time.

Wall Street will be looking for positivity from TNDM as it approaches its next earnings report date. The company is expected to report EPS of -$0.28, up 72.82% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $50.32 million, up 84.44% from the prior-year quarter.

TNDM's full-year Zacks Consensus Estimates are calling for earnings of -$0.72 per share and revenue of $264.27 million. These results would represent year-over-year changes of +71.76% and +43.73%, respectively.

Investors should also note any recent changes to analyst estimates for TNDM. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. TNDM is currently sporting a Zacks Rank of #3 (Hold).

The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 101, which puts it in the top 40% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Tandem Diabetes Care, Inc. (TNDM) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in